Current Breast Cancer Reports

, Volume 1, Issue 3, pp 127–130 | Cite as

Refining BRCA1 and BRCA2 penetrance estimates in the clinic



Genetic testing for mutations in BRCA1 and BRCA2 can provide important information to women and help guide clinical management decisions regarding interventions such as oophorectomy to reduce cancer risk. However, variability exists in risks of breast and ovarian cancer in individual BRCA1 and BRCA2 mutation carriers, with potential contributing factors including genotype-phenotype correlations, modifier genes, environmental and reproductive exposures, and the impact of interventions. Ultimately, the clinical goal is to provide individualized assessment of breast and ovarian cancer risk to BRCA1 and BRCA2 mutation carriers accounting for these variables to aid decision-making. This article discusses factors affecting the penetrance of cancer risks in BRCA1/2 mutation carriers.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Gen 1995, 56:265–271.Google Scholar
  2. 2.
    Begg CB, Haile RW, Borg A, et al.: Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008, 299:194–201.PubMedCrossRefGoogle Scholar
  3. 3.
    Antoniou A, Pharoah PD, Narod S, et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117–1130.PubMedCrossRefGoogle Scholar
  4. 4.
    Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25:1329–1333.PubMedCrossRefGoogle Scholar
  5. 5.
    Fodor FH, Weston A, Bleiweiss IJ, et al.: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998, 63:45–51.PubMedCrossRefGoogle Scholar
  6. 6.
    King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643–646.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee JS, John EM, McGuire V, et al.: Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev 2006, 15:359–363.PubMedCrossRefGoogle Scholar
  8. 8.
    Brose MS, Rebbeck TR, Calzone KA, et al.: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002, 94:1365–1372.PubMedGoogle Scholar
  9. 9.
    Evans DG, Shenton A, Woodward E, et al.: Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008, 8:155.PubMedCrossRefGoogle Scholar
  10. 10.
    Gayther SA, Warren W, Mazoyer S, et al.: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995, 11:428–433.PubMedCrossRefGoogle Scholar
  11. 11.
    Gayther SA, Mangion J, Russell P, et al.: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997, 15:103–105.PubMedCrossRefGoogle Scholar
  12. 12.
    Antoniou AC, Sinilnikova OM, Simard J, et al.: RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007, 81:1186–1200.PubMedCrossRefGoogle Scholar
  13. 13.
    Easton D, Pooley K, Dunning A, et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087–1093.PubMedCrossRefGoogle Scholar
  14. 14.
    Stacey S, Manolescu A, Sulem P, et al.: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007, 39:865–869.PubMedCrossRefGoogle Scholar
  15. 15.
    Antoniou AC, Spurdle AB, Sinilnikova OM, et al.: Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008, 82:937–948.PubMedCrossRefGoogle Scholar
  16. 16.
    Garcia-Closas M, Hall P, Nevanlinna H, et al.: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008, 4:e1000054.Google Scholar
  17. 17.
    Tjonneland A, Christensen J, Olsen A, et al.: Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2007, 18:361–373.PubMedCrossRefGoogle Scholar
  18. 18.
    Vachon CM, van Gils CH, Sellers TA, et al.: Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 2007, 9:217.PubMedCrossRefGoogle Scholar
  19. 19.
    Kiley J, Hammond C: Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol 2007, 50:868–877.PubMedCrossRefGoogle Scholar
  20. 20.
    Troisi R, Potischman N, Hoover RN: Exploring the underlying hormonal mechanisms of prenatal risk factors for breast cancer: a review and commentary. Cancer Epidemiol Biomarkers Prev 2007, 16:1700–1712.PubMedCrossRefGoogle Scholar
  21. 21.
    Michels KB, Mohllajee AP, Roset-Bahmanyar E, Beehler GP, Moysich KB: Diet and breast cancer: a review of the prospective observational studies. Cancer 2007, 109:2712–2749.PubMedCrossRefGoogle Scholar
  22. 22.
    Antoniou AC, Rookus M, Andrieu N, et al.: Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009, 18:601–610.PubMedCrossRefGoogle Scholar
  23. 23.
    Chang-Claude J, Andrieu N, Rookus M, et al.: Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2007, 16:740–746.PubMedCrossRefGoogle Scholar
  24. 24.
    Andrieu N, Goldgar DE, Easton DF, et al.: Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 2006, 98:535–544.PubMedCrossRefGoogle Scholar
  25. 25.
    Antoniou AC, Shenton A, Maher ER, et al.: Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2006, 8:R72.PubMedCrossRefGoogle Scholar
  26. 26.
    Brohet RM, Goldgar DE, Easton DF, et al.: Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007, 25:3831–3836.PubMedCrossRefGoogle Scholar
  27. 27.
    Narod SA, Sun P, Ghadirian P, et al.: Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001, 357:1467–1470.PubMedCrossRefGoogle Scholar
  28. 28.
    Colilla S, Kantoff PW, Neuhausen SL, et al.: The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 2006, 27:599–605.PubMedCrossRefGoogle Scholar
  29. 29.
    Ghadirian P, Lubinski J, Lynch H, et al.: Smoking and the risk of breast cancer among carriers of BRCA mutations. Int J Cancer 2004, 110:413–416.PubMedCrossRefGoogle Scholar
  30. 30.
    Brunet JS, Ghadirian P, Rebbeck TR, et al.: Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 1998, 90:761–766.PubMedCrossRefGoogle Scholar
  31. 31.
    Nkondjock A, Ghadirian P, Kotsopoulos J, et al.: Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer 2006, 118:103–107.PubMedCrossRefGoogle Scholar
  32. 32.
    Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616–1622.PubMedCrossRefGoogle Scholar
  33. 33.
    Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609–1615.PubMedCrossRefGoogle Scholar
  34. 34.
    Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009, 101:80–87.PubMedCrossRefGoogle Scholar
  35. 35.
    Kramer JL, Velazquez IA, Chen BE, et al.: Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005, 23:8629–8635.PubMedCrossRefGoogle Scholar
  36. 36.
    Domchek SM, Friebel TM, Neuhausen SL, et al.: Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006, 7:223–229.PubMedCrossRefGoogle Scholar
  37. 37.
    Kauff ND, Domchek SM, Friebel TM, et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008, 26:1331–1337.PubMedCrossRefGoogle Scholar
  38. 38.
    Meijers-Heijboer H, van Geel B, van Putten WL, et al.: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:159–164.PubMedCrossRefGoogle Scholar
  39. 39.
    Friebel TM, Domchek SM, Neuhausen SL, et al.: Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 2007, 7:875–882.PubMedCrossRefGoogle Scholar
  40. 40.
    Antoniou AC, Cunningham AP, Peto J, et al.: The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008, 98:1457–1466.PubMedCrossRefGoogle Scholar
  41. 41.
    Tuttle TM, Habermann EB, Grund EH, et al.: Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment, J Clin Oncol 2007, 25:5203–5209.PubMedCrossRefGoogle Scholar
  42. 42.
    US Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing: recommendation statement. Ann Internal Med 2005, 143:355–361.Google Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Cancer Risk Evaluation ProgramUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations